Ondansetron Tablet, Orally Disintegrating
Product Images NDC 65862-391

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ondansetron (NDC 65862-391). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ondansetronod-fig1 (Ondansetronod Fig1)

Ondansetronod-fig1 (Ondansetronod Fig1)
This is a description of a medication called Ondansetron Orally Disintegrating Tablets, USP. Each tablet contains Ondansetron USP 4. The package insert gives instructions on usage and administration. The tablets should be stored at a controlled room temperature of 20-25°C. They should not be removed from the package until immediately before use. The medication meets the USP Disintegration Test 2 and should be dispensed in a tight, light-resistant container. The medication is distributed by Aurobindo Pharma USA.*
FDA Label Image

Package Label-principal Display Panel (4 mg Blister Carton (3 x 10 Unit-dose))

Package Label-principal Display Panel (4 mg Blister Carton (3 x 10 Unit-dose))
This is a medication description for Ondansetron Orally Disintegrating Tablets, which require a prescription. Each contains 4 grams of Ondansetron USP, and a package should be stored between 20-30°C to maintain shelf life. The package contains 30 tablets, while the dosage and administration instructions should be followed as per the packaging. This particular medication is distributed by Aurobindo Pharma USA, Inc. The text includes a caution that the blister cards should be provided in a child-resistant container, and should not be used if blister packages are open, broken, or have missing medication.*
FDA Label Image

Package Label-principal Display Panel (8 mg (6,000 Tablets Bottle))

Package Label-principal Display Panel (8 mg (6,000 Tablets Bottle))
This is the packaging information for Ondansetron Orally Disintegrating Tablets, USP, manufactured by Aurobindo Pharma USA. Each package contains 30 tablets, each containing 8mg of Ondansetron USP. It is recommended to verify the standard dosage and administration from the packaging before use, which is stored at a temperature of 20-25°C (68-77°F). These tablets meet the USP Disintegration Test 2 and should be dispensed from a tight, light-resistant container per the USP guidelines. The package should not be opened until immediately before use. There is no additional information available.*
FDA Label Image

Package Label-principal Display Panel (8 mg Blister Carton (3 x 10 Unit-dose))

Package Label-principal Display Panel (8 mg Blister Carton (3 x 10 Unit-dose))
Ondansetron is a medication in the form of orally disintegrating tablets used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. This specific package contains 30 tablets and cannot be removed from the blister card until immediately prior to use. Ondansetron tablets should only be used as directed and should not be taken by individuals with phenylketonuria due to the presence of phenylalanine. The medication meets USP Disintegration Test 2 and should be stored at a controlled room temperature between 20-25°C (68-77°F) in a light-resistant container. This medication is manufactured and distributed by Aurobindo Pharma USA.*
FDA Label Image

Chemical Structure (Ondansetronod Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.